Cybin Inc
AMEX:CYBN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5
10.19
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
There is not enough data to reliably calculate the intrinsic value of CYBN.
The Intrinsic Value is calculated as the average of DCF and Relative values:
| US |
|
Eli Lilly and Co
NYSE:LLY
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Cybin is highly reliant on successful trial outcomes for CYB003 and other deuterated psilocybin analogs, meaning any clinical setbacks or prolonged timelines could significantly undermine investor confidence.
The regulatory landscape for psychedelics remains uncertain, and unanticipated delays in FDA or other global approvals could force Cybin to raise additional capital, diluting existing shareholders.
Intense competition from better-funded psychedelic firms and established biotech players may erode Cybin’s market share and hamper its ability to secure favorable partnerships.
Cybin’s leading candidate, CYB003, is progressing in clinical trials and, if approved, could position the company at the forefront of next-generation psychedelic treatments for major depressive and addiction disorders.
The company’s emphasis on proprietary deuterated psilocybin derivatives and novel delivery mechanisms may strengthen Cybin’s intellectual property moat and lead to differentiated product offerings.
Recent strategic acquisitions and research collaborations expand Cybin’s pipeline, potentially accelerating its path to commercialization and securing a strong foothold in the emerging psychedelic medicine market.
Revenue & Expenses Breakdown
Cybin Inc
Balance Sheet Decomposition
Cybin Inc
| Current Assets | 143.7m |
| Cash & Short-Term Investments | 118.7m |
| Receivables | 4.1m |
| Other Current Assets | 20.9m |
| Non-Current Assets | 67.2m |
| PP&E | 82k |
| Intangibles | 67.1m |
| Current Liabilities | 14.6m |
| Accounts Payable | 14.6m |
| Non-Current Liabilities | 44.5m |
| Long-Term Debt | 44.5m |
Free Cash Flow Analysis
Cybin Inc
| CAD | |
| Free Cash Flow | CAD |
Earnings Waterfall
Cybin Inc
|
Revenue
|
0
CAD
|
|
Operating Expenses
|
-147.4m
CAD
|
|
Operating Income
|
-147.4m
CAD
|
|
Other Expenses
|
24.5m
CAD
|
|
Net Income
|
-122.9m
CAD
|
CYBN Profitability Score
Profitability Due Diligence
Cybin Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Cybin Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
CYBN Solvency Score
Solvency Due Diligence
Cybin Inc's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Score
Cybin Inc's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CYBN Price Targets Summary
Cybin Inc
Dividends
Current shareholder yield for CYBN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?